Accuray Incorporated (ARAY)

Accuray's stock has experienced significant volatility and decline over the past six months. On May 6, 2026, Accuray reported its third-quarter fiscal year 2026 financial results, which missed Wall Street expectations, and the company withdrew its financial guidance for fiscal year 2026. On April 22, 2026, Accuray announced the date for its Q3 FY2026 financial results. On April 6, 2026, Paul Miele was appointed as Senior Vice President and Chief Commercial Officer. On February 4, 2026, Accuray reported its second-quarter fiscal year 2026 financial results, which also showed declining revenue and losses. On January 21, 2026, the company announced the date for its Q2 FY2026 financial results. On December 15, 2025, Accuray announced a transformation plan aimed at achieving approximately $25 million in annualized operating improvements and headcount reductions. On November 6, 2025, the company reported its first-quarter fiscal year 2026 results, which included year-over-year revenue declines and losses. In October 2025, a change in CEO was announced, along with pre-announced weaker profits.

Accuray's products and services exhibit some demand seasonality, with stronger demand historically in the first half of the fiscal year, particularly in China. Product revenue, in general, has been noted to be volatile, with some seasonal weakness being not unusual.

Accuray, Inc. is a radiation oncology company focused on developing, manufacturing, selling, and supporting precise radiation treatment solutions. They operate in the healthcare technology sector, specifically in surgical and medical instrument manufacturing. Their products include CyberKnife Systems, TomoTherapy Platforms, Accuray Precision Treatment Planning, iDMS Data Management, ClearRT Imaging Technology, Accuray Stellar Solution, Accuray Helix platform and Veterinary Oncology products. Accuray also provides services and support programs, including maintenance, training, and software upgrades.

Accuray has a global presence with over 1,000 radiation and radiosurgery systems installed in more than 700 practices across approximately 50 countries. The company's headquarters are in Madison, Wisconsin, with additional offices in California, Switzerland, Japan, Hong Kong, and China. They also have manufacturing facilities in the U.S. and China. Customer revenues are reported across the Americas, EIMEA, Japan, China, and Asia Pacific.

Accuray's brand reputation is characterized by its commitment to innovation in radiation therapy and improving patient outcomes. Recent financial struggles could indirectly affect investor confidence. However, the company continues to announce new product innovations and strategic partnerships, which generally contribute positively to its reputation within the medical community.

Institutional investors are the dominant shareholders of Accuray, Inc., holding a substantial majority of the company's shares. Major institutional owners include TCW Group Inc., BlackRock, Inc., Vanguard Group Inc., Weber Capital Management Llc /adv, Neuberger Berman Group LLC, Armistice Capital, Llc, Heartland Advisors Inc, Geode Capital Management, Llc, Renaissance Technologies Llc and State Street Corp. Insider ownership stood at 2.26% as of July 30, 2025, and increased from 4.73% to 5.07% in February 2026.